• Please log in or register to access this feature.

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

  1. Roger S McIntyre1,
  2. Miriam Cohen2,
  3. Jun Zhao2,
  4. Larry Alphs3,
  5. Thomas A Macek3,
  6. John Panagides2

Article first published online: 14 OCT 2009

DOI: 10.1111/j.1399-5618.2009.00748.x

Issue

Bipolar Disorders

Bipolar Disorders

Volume 11, Issue 7, pages 673–686, November 2009

Additional Information

How to Cite

McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L., Macek, T. A. and Panagides, J. (2009), A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders, 11: 673–686. doi: 10.1111/j.1399-5618.2009.00748.x

Author Information

  1. 1

    Department of Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada

  2. 2

    Schering-Plough, Summit, NJ

  3. 3

    Pfizer, Inc., Ann Arbor, MI, USA (at the time this research was conducted)

*Corresponding author: Roger S. McIntyre, MD, FRCPC Department of Psychiatry and Pharmacology University of Toronto Mood Disorders Psychopharmacology Unit University Health Network 399 Bathurst Street, MP 9-325 Toronto, Ontario, M5T 2S8, Canada Fax: 416-603-5368 E-mail: roger.mcintyre@uhn.on.ca

  1. This study was funded by Schering-Plough and Pfizer, Inc. All authors significantly contributed to the writing of this manuscript. RSM critically analyzed and interpreted the data. MC, LA, TAM, and JP were involved in the design and execution of the trial. JZ was responsible for the statistical analysis. Editorial support, which consisted of stylistic editing, proofreading, and formatting was provided by Complete Healthcare Communications, Inc., and was funded by Schering-Plough.

  2. RSM has received research funding from Wyeth, GlaxoSmithKline, Merck, Servier, and AstraZeneca; and has served as a consultant or speaker for AstraZeneca, Eli Lilly & Co., Janssen-Ortho, Schering-Plough, Wyeth, Lundbeck, GlaxoSmithKline, Oryx, Biovail, Pfizer, Prestwick, and Shire. MC, JZ, and JP are employees of Schering-Plough. LA and TAM were employed at Pfizer Global R&D at the time the study was conducted. The authors have no other commercial associations that might pose a conflict of interest in connection with the manuscript.

Publication History

  1. Issue published online: 14 OCT 2009
  2. Article first published online: 14 OCT 2009
  3. Received 2 December 2008, revised and accepted for publication 16 June 2009
Corrected by:

Corrigendum

Vol. 11, Issue 8, 904, Article first published online: 16 NOV 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (322K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (322K)